Oragenics, which recently announced that it had raised approximately $16.5 million for Phase 2 development of its OPN-002 neurosteroid nasal powder for the treatment of mild traumatic brain injury, says that Sterling Pharma Services will manufacture OPN-002 for an upcoming Phase 2b trial. Sterling is part of the INTO DPI development consortium along with DFE Pharma and Harro Höfliger.
Oragenics CEO Janet Huffman commented, “We are excited to partner with Sterling’s facility in Cary, North Carolina, to support the production of ONP-002. This partnership is a critical milestone in our path forward for Phase 2b clinical trials. This partnership reinforces our commitment to quality, efficiency, and US-based innovation and we believe this step will help streamline our clinical development strategy.”
Sterling Pharma Solutions Chief Commercial Officer Chad Telgenhof said, “We are pleased to be partnering with Oragenics for the GMP production of its lead molecule for clinical trials. Our scientific expertise in CNS therapies and our ability to meet critical timelines will support the continued path to market for this transformative drug candidate.”
Read the Oragenics press release
